A provider briefing on Entyvio (Vedolizumab) supply in 2026. Coverage of availability, prescribing considerations, cost, and patient access tools.
For gastroenterologists and other providers prescribing Entyvio (Vedolizumab) for inflammatory bowel disease, staying current on supply dynamics is essential to patient care. When access to a biologic becomes unreliable, treatment continuity suffers — and so do patient outcomes.
This briefing covers the current Entyvio supply landscape, prescribing implications, cost and coverage realities, and tools available to help your patients maintain access to this critical medication.
As of March 2026, Vedolizumab is not listed on the FDA Drug Shortage Database. Takeda Pharmaceuticals has not disclosed a formal supply disruption.
However, anecdotal reports from patients and practice administrators indicate intermittent access challenges at specialty pharmacies and infusion centers across the United States. These are not uniform — some regions experience more difficulty than others, and availability can fluctuate week to week.
The disconnect between "no official shortage" and real-world access barriers is a familiar pattern with specialty biologics, where distribution complexity, insurance logistics, and demand surges can create localized unavailability.
With both IV infusion (300 mg every 8 weeks after induction) and subcutaneous injection (108 mg every 2 weeks for maintenance) now approved for both UC and CD, providers have flexibility to match the formulation to the patient's clinical needs and access realities.
Consider the following when choosing between formulations:
Regardless of intended maintenance formulation, induction remains IV-based: 300 mg at weeks 0, 2, and 6. Ensure infusion center availability before initiating a new patient on Entyvio to avoid interruptions during the critical induction phase.
Key prescribing considerations:
Entyvio flows through a specialty distribution model:
Practices with in-house infusion suites and buy-and-bill arrangements may have more reliable access than those relying on external infusion centers. If your practice doesn't operate its own infusion suite, establishing relationships with multiple infusion center partners can provide backup when one location faces stock limitations.
Current 2026 pricing:
Insurance landscape:
Medfinder offers a provider-facing tool to check real-time availability of Entyvio (and other specialty medications) at pharmacies and infusion centers. This can be integrated into your care coordination workflow to proactively identify supply issues before they affect patients.
Takeda's EntyvioConnect program (1-844-368-9846) provides:
The biosimilar pipeline offers a medium-term outlook for improved supply and competition. Alvotech's AVT16 (IV) and AVT80 (SC) candidates showed positive Phase 3 results in early 2026. Polpharma is also advancing a biosimilar candidate. However, regulatory approval, patent considerations, and market launch timelines suggest biosimilar availability no earlier than 2028.
In the near term, the key strategy for providers is proactive supply management: verifying availability before prescribing, establishing multiple pharmacy and infusion center relationships, and leveraging formulation flexibility to keep patients on therapy.
While there is no official Entyvio shortage in 2026, the practical realities of specialty biologic access mean that providers must remain vigilant. Proactive coordination — using tools like Medfinder for Providers, engaging EntyvioConnect early in the prescribing process, and maintaining awareness of alternative formulations and biologics — can prevent treatment gaps that lead to disease flares and loss of response.
Related provider resources:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
